From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Emergency Medicine>
  4. Summary and Comment

Lorazepam Prevents Recurrent Alcohol-Related Seizures

When a patient has a seizure related to alcohol, it is uncertain whether acute treatment will prevent recurrence. Phenytoin is not effective in preventing alcohol-related seizures. The ability of lorazepam to prevent recurrent alcohol-related seizures was assessed in this randomized, prospective, double-blind trial.

Investigators enrolled 186 of 229 patients with alcohol-related seizures who were evaluated over 21 months at two hospitals in Boston. Exclusion criteria included signs of alcohol withdrawal and ingestion of drugs that could cause or protect against seizures. Patients were assigned to receive 2 mg of lorazepam (54%) or placebo. In the lorazepam group, 3 patients (3%) had another seizure within 6 hours, compared with 21 patients (24%) in the placebo group. The odds ratio for seizure with the use of placebo was 10.4 (95% confidence interval, 3.6 to 30.2; P<0.001). There were no complications associated with lorazepam. Seven patients in the placebo group and one in the lorazepam group were transported to an emergency department within 48 hours of discharge because of another seizure.

Comment: Intravenous lorazepam was effective in preventing recurrent alcohol-related seizures in this study. It appears that lorazepam did not simply delay recurrence, but actually prevented it. Given the safety of a single dose of lorazepam, it seems reasonable to advocate such treatment. Patients in alcohol withdrawal and those with more complicated presentations would obviously require a more aggressive approach.

— JG Adams

Published in Journal Watch Emergency Medicine May 1, 1999

Citation(s):

D'Onofrio G et al. Lorazepam for the prevention of recurrent seizures related to alcohol. N Engl J Med 1999 Mar 25 340 915-919.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Copyright © 1999. Massachusetts Medical Society. All rights reserved.